CD8A and neoplasm: Moreover, the flow cytometric results demonstrated that the combination use of XAV-939 and aPD-L1 significantly elevated the proportion of CD8+ T cells to 37% and CD8+IFN-γ+ T cells to 6.8% in the BMF-rich tumor microenvironment (Figures 5E–H), with only 23% CD8+ T cells and 2.6% CD8+IFN-γ+ T cells infiltrated into BMF-rich tumors after aPD-L1 monotherapy.